These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 15459427

  • 1. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens.
    Conte P, Guarneri V.
    Oncologist; 2004; 9 Suppl 4():28-37. PubMed ID: 15459427
    [Abstract] [Full Text] [Related]

  • 2. Bisphosphonates: clinical experience.
    Coleman RE.
    Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
    [Abstract] [Full Text] [Related]

  • 3. Toward new horizons: the future of bisphosphonate therapy.
    Lipton A.
    Oncologist; 2004; 9 Suppl 4():38-47. PubMed ID: 15459428
    [Abstract] [Full Text] [Related]

  • 4. Bisphosphonate treatment recommendations for oncologists.
    von Moos R.
    Oncologist; 2005; 10 Suppl 1():19-24. PubMed ID: 16264109
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A, Scher N, Williams G, Sridhara R, Li N, Chen G, Leighton J, Booth B, Gobburu JV, Rahman A, Hsieh Y, Wood R, Vause D, Pazdur R.
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [Abstract] [Full Text] [Related]

  • 9. Bisphosphonates for breast cancer.
    Pavlakis N, Schmidt R, Stockler M.
    Cochrane Database Syst Rev; 2005 Jul 20; (3):CD003474. PubMed ID: 16034900
    [Abstract] [Full Text] [Related]

  • 10. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD.
    Clin Ther; 2005 Apr 20; 27(4):361-76. PubMed ID: 15922811
    [Abstract] [Full Text] [Related]

  • 11. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid.
    Maxwell C, Swift R, Goode M, Doane L, Rogers M.
    Clin J Oncol Nurs; 2003 Apr 20; 7(4):403-8. PubMed ID: 12929273
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Bisphosphonates and metastatic breast carcinoma.
    Lipton A.
    Cancer; 2003 Feb 01; 97(3 Suppl):848-53. PubMed ID: 12548585
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.
    Berenson JR, Vescio RA, Rosen LS, VonTeichert JM, Woo M, Swift R, Savage A, Givant E, Hupkes M, Harvey H, Lipton A.
    Clin Cancer Res; 2001 Mar 01; 7(3):478-85. PubMed ID: 11297237
    [Abstract] [Full Text] [Related]

  • 19. Adverse effects of bisphosphonates: current issues.
    Diel IJ, Bergner R, Grötz KA.
    J Support Oncol; 2007 Mar 01; 5(10):475-82. PubMed ID: 18240669
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.